Abstract 1504
Background
Weight loss prior to cancer treatment carry a negative impact on clinical outcomes. However, few studies have addressed whether weight assessment over time is plagued by high dropout rates and whether weight change carries a prognostic association in the same manner as it does at baseline.
Methods
A pooled analysis of individual patient data was undertaken among non-small cell lung cancer patients who participated in prospective cancer treatment trials from the Alliance for Clinical Trials in Oncology from 1998-2008. This study examined 1) rates of missing weight data over time and 2) the prognostic association of weight beyond baseline assessment.
Results
822 chemotherapy-treated patients were examined. 659 (80%) were still on treatment at the beginning of cycle 2. Weight was available for 656 (80%) patients. However, by cycles 3 and 4, weight was available for only 448 (55%) and 384 (47%) patients, respectively. From baseline to immediately prior to cycle 2, 224 patients (34% of 656) lost more than 2% baseline weight, and 226 (34%) lost between 0 and 2%. With respect to prognostic associations, the median survival time from the beginning of cycle 2 was 6.9, 10.9, and 13.0 months for patients with weight loss of 2% or more, loss of < 2%, and those with weight gain, respectively. In multivariate analyses, after adjustment for age, gender, performance score, type of treatment, and body mass index, weight loss of 2% or more was associated with poor survival compared to weight loss of < 2% (hazard ratio (HR) = 1.57; 95% CI [1.27 to 1.95]; P <.001). Although weight gain was not associated with improved overall survival, it was associated with better progression-free survival outcomes (HR = 0.81; 95% CI [0.66 to 0.99]; P=.04).
Conclusions
Weight is a clinically useful endpoint and should be integrated into cancer cachexia trials because of its ease of frequent measurement and sustained prognostic association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fred C and Katherine B Andersen Foundation and the United States National Cancer Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract